Is talcum powder safe, and what about cancer and asbestos?

What talc is, and why asbestos comes up

Talc is a soft magnesium silicate mineral used in body powders, makeup and many industrial products. Talc and asbestos can occur close together in the earth, so talc can be contaminated. FDA says there is "potential for contamination" and has run repeated tests of talc-containing cosmetics from 2019 to 2023³. IARC notes that industry tests have often been too insensitive to rule asbestos out, and it left "talc containing asbestos" in Group 1, "carcinogenic to humans"⁶. Mesothelioma has been reported in people whose only known asbestos exposure was cosmetic talc, typically after decades of use⁴.

Ovarian cancer: hazard versus exposure

Talc applied near the genitals may travel up the reproductive tract. In human biopsies talc has been found in the pelvis, including the ovary, though most animal studies saw no movement from the perineum to the ovary⁶. Epidemiology is split by design:

• Case-control studies. Pooling 8,525 cases and 9,859 controls gave an odds ratio of 1.24 for ovarian cancer in powder users⁷. A meta-analysis of 27 studies gave 1.31⁸. Frequent use (at least twice a week) gave 1.47⁹.
• Cohort studies. Pooling four US cohorts of 252,745 women gave a hazard ratio of 1.08, which was not statistically significant. It translates to about 9 extra cases per 10,000 women by age 70 (95% CI -2 to 19)¹⁰.

Ovarian cancer is uncommon, so even a real 20 to 30% relative rise would add little absolute risk¹.

Babies

For infants the main danger is inhalation. Severe lung injury after accidental inhalation of baby powder is well described².

What to do

Nothing in the evidence demands panic: in the largest cohort analysis, fewer than 1% of women (2,168 of 252,745) developed ovarian cancer over about 11 years¹⁰. But powder is optional, so leaving it out is a cheap precaution. If you do use a powder, keep it off broken skin and away from the face⁵. See also Hidden Chemicals in Your Daily Routine.

Case-control studies and meta-analyses

A meta-analysis of 24 case-control studies (13,421 cases) and three cohorts (890 cases, 181,860 person-years) found an overall odds ratio of 1.31 (95% CI 1.24 to 1.39) for any perineal talc use. It was 1.35 (1.27 to 1.43) in case-control studies but 1.06 (0.90 to 1.25) in cohorts. More than 3,600 lifetime applications gave 1.42 (1.25 to 1.61). Serous and endometrioid tumors were raised; mucinous and clear cell were not⁸. The pooled analysis of eight case-control studies found no significant trend with number of applications (P = 0.17) and no increase among women who used only non-genital powder⁷. In the African American Cancer Epidemiology Study (584 cases, 745 controls), genital powder gave 1.44 (1.11 to 1.86), with dose-response; non-genital use was also associated¹¹. A 2022 meta-analysis of 11 studies found frequent use (twice a week or more) gave 1.47 (1.31 to 1.65). One author had served as a paid expert witness for plaintiffs⁹.

Cohort studies

In the Women's Health Initiative, 61,576 postmenopausal women were followed for 12.4 years; 52.6% had ever used perineal powder. There were 429 ovarian cancers, and the hazard ratio for ever use was 1.06 (0.87 to 1.28)¹². Four US cohorts then pooled 252,745 women with 2,168 cancers over a median 11.2 years. The hazard ratio was 1.08 (0.99 to 1.17) for ever use, 1.09 (0.97 to 1.23) for frequent use and 1.01 (0.82 to 1.25) for 20 years or more. The estimated risk difference by age 70 was 0.09% (-0.02% to 0.19%). Among women with an open (patent) reproductive tract the ratio was 1.13 (1.01 to 1.26), though the test for difference was not significant (P = .15). The authors noted the study might have been underpowered¹⁰.

Why the results differ

Case-control studies ask women with cancer to recall decades-old habits, so bias is possible. Cohort studies recorded powder use once, at enrollment, which measures lifetime exposure crudely¹². IARC's 2024 review rated the human evidence "limited": bias from misclassified exposure could not be excluded and confounding by asbestos in the talc could not be ruled out⁶. That is why talc is Group 2A. Other proposed explanations include contaminants such as quartz and inflammation from other ingredients¹. FDA's own summary is that studies "have not conclusively demonstrated" a link³.

Asbestos

A case series of 75 people (64 women) with mesothelioma, whose only known asbestos exposure was repeated cosmetic talc use, reported a mean latency of 50 years and mean exposure of 33 years. In the 11 whose tissue was examined, all had anthophyllite or tremolite asbestos. These were medicolegal referrals, with no denominator, and the authors had testified mainly for plaintiffs⁴. FDA advised consumers in 2019 to stop using certain products that tested positive. A proposed rule on testing methods, published in December 2024, was withdrawn on 28 November 2025, so no final testing rule is in place³.

The cosmetic-safety panel's view

The Cosmetic Ingredient Review Expert Panel concluded that talc is safe in cosmetics at present practices of use and concentration, and advised that it not be applied where the skin barrier is missing or significantly disrupted. Its reasoning relied only on studies of talc that did not contain asbestos⁵. That is the key caveat: the conclusion assumes asbestos-free talc, which is exactly what is hard to guarantee.

Bottom line

Confidence 3 of 5. A modest association with ovarian cancer is seen in case-control studies and weakly in cohorts; causation is unproven. Asbestos-contaminated talc can cause mesothelioma. Powder is optional, and leaving it out is a low-cost precaution.